z-logo
open-access-imgOpen Access
Improved long‐term survival in D utch heart transplant patients despite increasing donor age: the R otterdam experience
Author(s) -
Zijlstra Laurien E.,
Constantinescu Alina A.,
Manintveld Olivier,
Birim Ozcan,
Hesselink Dennis A.,
Thiel Robert,
Domburg Ron,
Balk Aggie H. M.,
Caliskan Kadir
Publication year - 2015
Publication title -
transplant international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.998
H-Index - 82
eISSN - 1432-2277
pISSN - 0934-0874
DOI - 10.1111/tri.12503
Subject(s) - medicine , cohort , immunosuppression , transplantation , heart transplantation , tacrolimus , surgery
Summary Over the past decades donor and recipient characteristics and medical management of heart transplantation ( HT ) patients have changed markedly. We studied the impact of these changes on long‐term clinical outcome. Data of all consecutive HT recipients in our center have been collected prospectively. Cohort A ( n  = 353) was defined as the adult pts transplanted between 1984 and 1999 and was compared with cohort B ( n  = 227) transplanted between 2000 and 2013. Compared with cohort A, recipients in cohort B had older donors (mean age 29 vs. 43 years, donors aged >50 year: 2% vs. 33%, respectively). Survival at 1 and 10 years in cohort A vs. B was 89% vs. 86% and 53% vs. 68%, respectively ( P  = 0.02). Cohort B pts were treated more often with tacrolimus‐based immunosuppression (77% vs. 22%; P  = <0.0001) and early statins post‐ HT (88% vs. 18%; P  = 0.0001), while renal function was better conserved at 5 and 10 years ( P  = 0.001 and 0.02). Multivariate analysis showed significant reduction in 10‐year mortality with tacrolimus‐based immunosuppression ( HR 0.27 and 95% CI 0.17–0.42), hypertension post‐HT ( HR 0.5, 95% CI 0.36–0.72), and revascularization ( HR 0.28, 95% CI 0.15–0.52). In spite of the use of much older donors, the long‐term outcome after HT has improved considerably in the last decade, probably due to the introduction of newer treatment modalities.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here